Please login to the form below

Not currently logged in
Email:
Password:

Chiesi extends research deal with NiKem

Chiesi Farmaceutici is to extend its research collaboration with NiKem Research, focused on developing treatments within the respiratory therapeutic area

Chiesi Farmaceutici is to extend its research collaboration with NiKem Research, focused on developing treatments within the respiratory therapeutic area.

The two companies have been working together since 2001, with the new deal extending their efforts until 2014.

The collaboration will see NiKem continue its work providing services such as design, lead optimisation and biochemical pharmacology within different therapeutic areas on a fee-for-service basis.

Italy-based Chiesi specialises in products for respiratory pathologies, special care medicine and cardiovascular diseases, with the extended NiKem agreement focused on respiratory illnesses such as asthma and COPD.

Giuseppe Giardina, CEO of NiKem, said: "The scientific and business relationship with Chiesi is rock solid and the current extension follows 10 years of continuous success for both parties in collaborating to identify novel compounds eligible to candidate status for clinical development."

6th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...

Infographics